Composition with soothing effect, preparation method and use thereof

Abstract

This application discloses a soothing composition comprising polydeoxyribonucleotides and ectoine or its derivatives, as well as a preparation method and use of the composition. The composition provided herein combines two main components, polydeoxyribonucleotides and ectoine or its derivatives, overcoming the drawback of single-functionality bioactive substances. The combination of polydeoxyribonucleotides and ectoine or its derivatives can synergistically enhance efficacy, effectively soothing sensitive skin and accelerating the skin's repair process.

Description

Technical Field

[0001] This application relates to the field of cosmetic technology, specifically to a composition with soothing effect, its preparation method and use Background Art

[0002] Normal human aging is an inevitable natural process. The physiological changes that occur during aging primarily manifest in the loss of tissue cells and constituent substances, a slowing of the body's metabolic rate, and decreased organ and organ function, ultimately leading to skin problems such as uneven skin tone, dullness, and dark spots. While aging is inevitable, it can be slowed down. Maintaining skin hydration and replenishing nutrients are key measures to delay aging. At the same time, many adolescents experience breakouts, which can lead to mild to moderate acne, which can be difficult to heal and cause skin damage. Using bioactive molecules to mitigate the effects of mild to moderate acne on adolescents is a key research topic. With the rapid advancement of science and technology and the continuous improvement of people's living standards, young people are increasingly choosing laser photorejuvenation for skin care. While laser photorejuvenation can effectively treat dull skin and improve pore size, it also requires careful postoperative sun protection and early postoperative hyperpigmentation. Effectively alleviating stress symptoms after laser photorejuvenation is also a crucial topic in urgent need of research.

[0003] How to find a simple, convenient, safe and effective way of use to compound different bioactive molecules to achieve a synergistic effect, and then alleviate skin aging, promote the healing of mild to moderate acne, and provide effective care after photorejuvenation surgery has become an important research direction. Summary of the Invention

[0004] In order to solve the technical problems in the prior art, the present application provides a composition that can soothe the skin, and its preparation method and use. Specifically, the present application adopts the following technical solutions:

[0005] 1. A composition with soothing effect, comprising polydeoxyribonucleotide and ectoine or its derivatives.

[0006] 2. The composition according to item 1, wherein the ectoine or its derivative is selected from one or more of ectoine, ectoine methyl ester, and hydroxyectoine.

[0007] 3. The composition according to item 1 or 2, wherein the mass ratio of ectoine or its derivative to polydeoxyribonucleotide is (0.1-20):1.

[0008] 4. The composition according to any one of items 1 to 3, further comprising other active ingredients and / or excipients.

[0009] 5. A skin care product comprising the composition according to any one of items 1 to 4.

[0010] 6. The skin care product according to item 5, in terms of weight percentage in the composition,

[0011] The content of ectoine or its derivatives is 0.01-4.0%, and the content of polydeoxyribonucleotide is 0.01-0.5%.

[0012] 7. The skin care product according to item 5 or 6, wherein the skin care product comprises a skin repair liquid, a liquid application essence or a skin spray.

[0013] 8. A method for preparing the skin care product according to any one of items 5 to 7, comprising:

[0014] The composition described in any one of items 1 to 4 is added to an aqueous solution and stirred thoroughly until uniform to obtain the skin care product.

[0015] 9. Use of the composition according to any one of items 1 to 4, the skin care product according to any one of items 5 to 6, or the skin care product prepared according to the method of item 8 for soothing skin.

[0016] Effects of the Invention

[0017] The skin care composition provided in the present application includes polydeoxyribonucleotides, ectoine or its derivatives, and combines the two main ingredients to overcome the defect of single functionality of biologically active substances. The compound polydeoxyribonucleotides and ectoine or its derivatives can synergistically enhance the effect, effectively soothe sensitive skin, and accelerate the skin repair process. DETAILED DESCRIPTION

[0018] The following description of exemplary embodiments of the present application includes various details of the embodiments of the present application to facilitate understanding, and should be considered as merely exemplary. Therefore, those skilled in the art will recognize that various changes and modifications may be made to the embodiments described herein without departing from the scope and spirit of the present application. Similarly, for the sake of clarity and conciseness, descriptions of well-known functions and structures are omitted in the following description.

[0019] The present application provides a composition with soothing effect, comprising polydeoxyribonucleotides and ectoine or its derivatives.

[0020] The polydeoxyribonucleotides (PDRNs) described in this application conform to the general definition in the field. These DNA fragments are extracted from salmon cells. As a cosmetic and pharmaceutical raw material, PDRNs are widely used in medical beauty, daily chemical products, skin care products, medical devices, and pharmaceuticals.

[0021] The ectoine of the present application conforms to the general definition in the art, and its chemical name is 2-methyl-1,4,5,6,-tetrahydropyrimidine-4-carboxylic acid. It is an amino acid derivative present in microorganisms and belongs to cyclic amino acids. The ectoine derivatives in the present application are not limited and can be derivatives of any type of ectoine in the art, as long as they can be used in combination with polydeoxyribonucleotides to soothe the skin, including but not limited to ectoine modified with chemical groups or salts and esters of ectoine. In a specific embodiment, the ectoine or its derivatives are selected from one or more of ectoine, ectoine methyl ester, and hydroxyectoine.

[0022] The present application innovatively discovered that polydeoxyribonucleotides and ectoine or its derivatives can synergistically enhance their effectiveness, not only exerting their respective effects, but also having a better effect in soothing sensitive skin and accelerating the skin repair process when used in combination.

[0023] In the combination of the present application, the respective amounts of the ectoine or its derivatives and the polydeoxyribonucleotides are not limited, as long as the combination can soothe the skin. In a specific embodiment, the mass ratio of the ectoine or its derivatives to the polydeoxyribonucleotides is (0.1-20):1, for example, it can be 0.2:1, 0.3:1, 0.4:1, 0.5:1, 0.6:1, 0.7:1, 0.8:1, 0.9:1, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1.

[0024] The molecular weight of the polydeoxyribonucleotide is not limited. In a specific embodiment, the molecular weight is preferably 40-800KD, for example, 40KD, 50KD, 60KD, 100KD, 200KD, 50KD, 300KD, 350KD, 400KD, 450KD, 500KD, 550KD, 600KD, 650KD, 700KD, 750KD, more preferably 500-800KD.

[0025] The composition described herein may further include other active ingredients and / or excipients.

[0026] The other active ingredients include but are not limited to moisturizing ingredients, anti-aging ingredients, whitening ingredients, anti-inflammatory ingredients, etc.

[0027] In a specific embodiment, the moisturizing ingredient includes one or more of glycerin, butylene glycol, pentylene glycol, polyethylene glycol, propylene glycol, hexylene glycol, xylitol, polypropylene glycol, sorbitol, sodium lactate, urea, hydroxyethyl urea, methyl glucose polyether, chitin derivatives, trehalose, tremella polysaccharide, panthenol, ceramide, and natural plant extracts.

[0028] The auxiliary materials include acid-base regulator, osmotic pressure regulator, water and the like.

[0029] The present application also provides a skin care product comprising the above composition.

[0030] In a specific embodiment, in the skin care, the percentage by weight of the above composition is:

[0031] The content of ectoine or its derivatives is 0.01-4.0%, for example, 0.02%, 0.05%, 0.1%, 0.2%, 0.3%, 0.5%, 1%, 1.5%, 2%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, 3%, 3.1%, 3.2%, 3.3%, 3.4%, 3.5%, 3.6%, 3.9%; the content of polydeoxyribonucleotides is 0.01-0.5%, for example, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09, 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.36%, 0.37%, 0.38%, 0.39%;

[0032] In a preferred embodiment, the amount of ectoine or its derivatives is 0.01-2.0%, and the amount of polydeoxyribonucleotide is 0.01-0.2%;

[0033] In a further preferred embodiment, the content of ectoine or its derivatives is 0.05-1.0%, and the content of polydeoxyribonucleotide is 0.05-0.1%.

[0034] In a specific embodiment, the skin care contains a moisturizing ingredient, which is expressed as a percentage by weight in the above composition.

[0035] The moisturizing component is 4.0-10.0%, for example, it can be 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, 10.0%, preferably 5.0-9.0%; more preferably 6.0-8.0%.

[0036] The moisturizing ingredients may be any one or more of the above.

[0037] The present application further provides a method for preparing any of the above-mentioned skin care products, comprising:

[0038] The above composition is added to an aqueous solution and stirred thoroughly until uniform to obtain the skin care product.

[0039] In a specific embodiment, polydeoxyribonucleotides and ectoine or its derivatives are added to an aqueous solution and stirred thoroughly until the solution is uniform to obtain the skin care product.

[0040] In a specific embodiment, the aqueous solution used in the method may contain other active ingredients and / or excipients. These other active ingredients and / or excipients may be added to the aqueous solution after the polydeoxyribonucleotide, ectoine or its derivatives are added to the aqueous solution, or may be added to the aqueous solution before the polydeoxyribonucleotide, ectoine or its derivatives are added to the aqueous solution, or may be added to the aqueous solution simultaneously with the polydeoxyribonucleotide, ectoine or its derivatives, so that the aqueous solution contains other active ingredients and / or excipients.

[0041] The other active ingredients or excipients are as described above.

[0042] The present application further provides the use of any of the above compositions or the above skin care products or the skin care products prepared by any of the above methods in soothing skin.

[0043] Any of the skin care products described above can be any form or function of care products in this field, including but not limited to lotions, lotions, ointments, creams, essences, sunscreens, oils, body toners, bath products, eye skin care products, facial masks, facial cleansers, makeup removers, foundations, pressed powders, rouges, body makeup, eyebrow pencils, eyeshadows, eyelids, eye hair, eye makeup removers, lip balms, lip glosses, plain lipsticks, lip liners, shampoos, shaving products, sprays, exfoliators, hair removers, etc.

[0044] In some embodiments of the present application, the skin care product is selected from any one of a skin repair solution, a patch essence, and a skin spray.

[0045] The composition provided herein includes polydeoxyribonucleotides and ectoine or its derivatives. The combination of ectoine or its derivatives and polydeoxyribonucleotides can achieve a synergistic effect, having a synergistic effect in soothing and improving skin conditions, and can effectively maintain a healthy skin microenvironment.

[0046] Example

[0047] This application provides general and / or specific descriptions of the materials and experimental methods used in the experiments. In the following examples, unless otherwise specified, % represents wt%, i.e., percentage by weight. Reagents or instruments used without manufacturer indication are commercially available conventional reagents. Table 1 lists the sources of the main raw materials used in the examples.

[0048] Table 1 Sources of the main raw materials used in the examples

[0049] raw material Manufacturer Ectoin Bloomage Biotech Co., Ltd. Hydroxyectoine Bloomage Biotech Co., Ltd. Ectoin methyl ester Bloomage Biotech Co., Ltd. polydeoxyribonucleotides Runhui Biotechnology (Weihai) Co., Ltd.

[0050] Example 1

[0051] The skin care product is prepared by the following method,

[0052] 0.01% of ectoine and 0.1% of polydeoxyribonucleotide (500KD) are added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0053] Example 2

[0054] 0.1% of ectoine and 0.1% of polydeoxyribonucleotide (500KD) are added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0055] Example 3

[0056] 0.2% of ectoine and 0.1% of polydeoxyribonucleotide (500KD) are added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0057] Example 4

[0058] 1.0% of ectoine and 0.1% of polydeoxyribonucleotide (500KD) are added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0059] Example 5

[0060] 2.0% of ectoine and 0.1% of polydeoxyribonucleotide (500KD) are added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0061] Example 6

[0062] 1.0% of ectoine and 0.2% of polydeoxyribonucleotide (500KD) are added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0063] Example 7

[0064] 0.2% of ectoine and 0.1% of polydeoxyribonucleotide (700KD) are added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0065] Example 8

[0066] 0.2% of ectoine methyl ester and 0.1% of polydeoxyribonucleotide (500KD) are added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0067] Example 9

[0068] 0.2% of ectoine, 0.1% of polydeoxyribonucleotide (500KD) and 0.2% of glycerol are added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0069] Example 10

[0070] 0.01% of ectoine and 0.2% of polydeoxyribonucleotide (500KD) are added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0071] Comparative Example 1

[0072] 0.1% polydeoxyribonucleotide (500KD) is added to the aqueous solution, stirred thoroughly until uniform, and allowed to stand to obtain a skin care product.

[0073] Comparative Example 2

[0074] 0.2% polydeoxyribonucleotide (500KD) is added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0075] Comparative Example 3

[0076] 0.2% polydeoxyribonucleotide (700KD) was added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0077] Comparative Example 4

[0078] 0.01% of ectoine is added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0079] Comparative Example 5

[0080] 0.1% of ectoine is added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0081] Comparative Example 6

[0082] 0.2% of ectoine is added to the aqueous solution, fully stirred until uniform, and allowed to stand to obtain a skin care product.

[0083] Comparative Example 7

[0084] 1.0% of ectoine was added to the aqueous solution, stirred thoroughly until uniform, and allowed to stand to obtain a skin care product.

[0085] Comparative Example 8

[0086] 2.0% of ectoine was added to the aqueous solution, stirred thoroughly until uniform, and allowed to stand to obtain a skin care product.

[0087] Table 2 Specific information of skin care products in each embodiment and comparative example

[0088]

[0089]

[0090] Test Example 1 Soothing Efficacy Test

[0091] Histamine is a chemical mediator found in the cytoplasmic granules of basophils and mast cells in the human body. The level of histamine release is related to skin allergies, itching, and other symptoms. Studies have shown that inhibiting histamine release can soothe the skin.

[0092] First, use a pipette to aspirate DMEM medium to disperse guinea pig mast cells and count them using a Hemacytometer. Then dilute the cells with DMEM to a concentration of 5×10 4 The diluted cell solution was inoculated into 6-well pertri dishes, with each well containing about 1 mL, i.e. 0.5×10 7cells / Well. Place it in an incubator at 37°C and 5% CO2 and culture it for 24 hours. After 24 hours, place the 6Well pertri dish under ultraviolet light to induce an allergic reaction in the cells and release histamine. At the same time, the sample to be tested is diluted with DMEM culture medium. After the sample is added, it is placed in an incubator at 37°C and 5% CO2 and cultured for 24 hours. After 24 hours, 200 microliters of culture medium are transferred for histamine derivatization reaction. Take 100ul of culture medium and put it into a 2mL tube. Add saturated NaHCO3 solution and dansyl chloride solution in turn. Cover and vortex to mix evenly. Then react at room temperature in the dark for 1 hour. After reacting for 1 hour, add 20% ammonia-acetonitrile solution and let it stand for 30 minutes to terminate the reaction. After adding 100ul of acetonitrile, vortex to mix evenly and pass through a 0.45um filter membrane for HPLC analysis. The histamine release inhibition rate of the embodiment and the comparative example was measured respectively.

[0093] We verified the additive effect of the combination using King's formula: Q = E(a+b) / (Ea+Eb-Ea×Eb) (where Q < 0.55 is significantly antagonistic, Q = 0.55-0.85 is antagonistic, Q = 0.85-1.15 is additive, and Q > 1.15 is enhancing).

[0094] For example, when the concentration of ectoine or its derivatives is 0.01%, the histamine release inhibition rate is 17%, as shown in Comparative Example 3; when the concentration of polydeoxyribonucleotide is 0.1%, the inhibition rate is 26%, as shown in Comparative Example 1; when the concentration of ectoine or its derivatives is 0.01% and the concentration of polydeoxyribonucleotide is 0.1%, the inhibition rate of the combination of the two is 46%, as shown in Example 1, then,

[0095] Ea = inhibition rate at a concentration of 0.01% of ectoine or its derivatives = 17%;

[0096] Eb = inhibition rate at a polydeoxyribonucleotide concentration of 0.1% = 26%;

[0097] E(a+b) = inhibition rate of the combination of 0.01% ectoine or its derivative and 0.1% polydeoxyribonucleotide = 46%,

[0098] Substituting into the formula we can get Q 依克多因或其衍生物-0.01％与多聚脱氧核糖核苷酸-0.1％ =1.19.

[0099] The Q values ​​of the above concentration combinations are also obtained according to the above formula.

[0100] The measurement results are shown in Table 3.

[0101] Table 3. Histamine release inhibition rate results of the compositions prepared in various examples and comparative examples

[0102]

[0103]

[0104] As can be seen from Table 3, skin care composition examples 1-10 can effectively inhibit histamine release. The ectoine or its derivatives and polydeoxyribonucleotides in the skin composition prepared by the present application can effectively improve the histamine release inhibition rate, which is far better than the histamine release inhibition rate of a single component, indicating that ectoine or its derivatives and polydeoxyribonucleotides can play a synergistic role in soothing.

[0105] Test Example 2: Soothing Effect Test on Human Skin

[0106] Test subjects: 40 volunteers with sensitive skin such as erythema, itching, and peeling were recruited and randomly divided into 4 groups, with 10 people in each group.

[0107] Sample usage: Apply evenly twice a day, 1.0 mL each time, for 30 consecutive days. No other products can be used during this period. A blank control group (no product) should be set up.

[0108] Test results: After the trial, the volunteers' skin conditions were observed and divided into three levels: significant effect (no erythema, itching, or peeling), average effect (no peeling or itching), and poor effect. The results of the skin soothing changes of each example and comparative example are shown in Table 4.

[0109] Table 4. Skin soothing results of the compositions of various examples and comparative examples

[0110] Group Significant effect / person Average effect / person Poor effect / person Example 3 10 0 0 Comparative Example 1 2 5 3 Comparative Example 2 1 6 3 Blank control group 0 0 10

[0111] As can be seen in Table 4, the subjects experienced excellent skin soothing effects after using the skin care composition of the present application, with symptoms such as erythema, itching, and peeling being significantly alleviated, while the effects of Comparative Examples 1-2 were average, and the blank control group had no effect. This indicates that the polydeoxyribonucleotides, ectoine, and their derivatives in the skin care composition prepared by the present application have a synergistic effect in soothing and improving skin conditions, and can effectively maintain a healthy skin microenvironment.

[0112] Although the embodiments of the present application are described above, the present application is not limited to the above-mentioned specific embodiments and application fields. The above-mentioned specific embodiments are merely illustrative and instructive, and not restrictive. A person of ordinary skill in the art, under the guidance of this specification and without departing from the scope of protection of the claims of this application, can also make many forms, all of which fall within the scope of protection of this application.

Claims

1. A composition having a soothing effect, wherein: It is composed of polydeoxyribonucleotide and ectoine or its derivatives; Wherein, the mass ratio of ectoine or its derivative to polydeoxyribonucleotide is (1-20):1; Wherein, the molecular weight of the polydeoxyribonucleotide is 400~800KD; Wherein, the ectoine or its derivative is selected from one or more of ectoine, ectoine methyl ester and hydroxyectoine.

2. The composition according to claim 1, wherein Other active ingredients and / or excipients may also be included.

3. A skin care product comprising the composition according to claim 1 or 2.

4. The skin care product according to claim 3, in percentage by weight in the composition, The amount of ectoine or its derivatives is 0.01-4.0%, and the amount of polydeoxyribonucleotide is 0.01-0.5%.

5. The skin care product according to claim 3 or 4, wherein The skin care products include skin repair liquid, liquid application essence or skin spray.

6. A method for preparing the skin care product according to any one of claims 3 to 5, comprising: The composition according to claim 1 or 2 is added to an aqueous solution and stirred thoroughly until uniform to obtain the skin care product.

7. Use of the composition according to claim 1 or 2 in preparing a skin care product for soothing skin.

Images